Although indications began to appear as early as mid-February, it took another six weeks to confirm the worst fears about the SARS-CoV-2 virus that causes COVID-19: asymptomatic transmission was a reality. Suddenly, there was the realization that anyone could be a carrier. Accord- ingly, effective, accurate testing took on new importance. In the absence of a vaccine, testing was all that could ensure that people could return to the workplace or school with the assurance they wouldn’t infect others, and with the peace of mind that those around them were safe, too. In this unprecedented situation, when a rapid response was essential, the investment in innovative technologies paid dividends. A prime example is LabVantage Solutions’ purpose-built COVID-19 LIMS, built on the company’s

Join for free to read